HC Wainwright Reiterates Buy Rating on GMAB
HC Wainwright maintains its buy rating on GMAB with a $38 target, a 46.92% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on GMAB with a $38 price target on June 23, 2026.
- HC Wainwright's $38 price target implies 46.92% upside from Genmab A/S's ($GMAB) current $25.86 share price.
- GMAB shares were trading around $25.61 on Tuesday, with various institutional investors adjusting their stakes.
- Insider Judith Klimovsky sold shares on June 17, 2025, while analysts maintain positive outlooks.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating for GMAB, setting a price target of $38 as of June 23, 2026. Analyst Raghuram Selvaraju continues to see potential in the stock, maintaining the positive outlook.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in GMAB
Several institutional investors have recently adjusted their positions in GMAB. Orbis Allan Gray Ltd reduced its holdings by 1,492,884 shares, ending with 12,925,578 shares valued at approximately $346.8 million, marking a 10.4% decrease. AllianceBernstein L.P. also trimmed its stake by 1,319,945 shares, now holding 9,557,149 shares worth about $294.4 million, a 12.1% reduction. On the other hand, Paradigm Biocapital Advisors LP increased its holdings by 928,002 shares, bringing its total to 7,967,836 shares valued at $213.8 million, a 13.2% increase. Arrowstreet Capital slightly decreased its position, while Renaissance Technologies LLC notably increased its stake by 921,700 shares, a 26.4% jump.
Genmab A/S Stock Down 22.2%
On Tuesday, GMAB shares were trading near $25.61. The stock has seen various institutional adjustments and continues to be a point of focus for analysts and investors alike.
$GMAB price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Genmab A/S
Insider Judith Klimovsky sold 1,300 shares at an average price of $51.69 and another batch of 1,300 shares at $52.00 on June 17, 2025. Previously, on March 1, 2024, she sold 1,200 shares at $275.00, with one of these transactions being planned.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its buy rating on GMAB with a $38 price target. Earlier, on April 30, 2026, the firm maintained the same rating and target. Wolfe Research initiated coverage with a buy rating and a $32 target on March 27, 2026, while Wells Fargo also started coverage with a buy rating, setting a $40 target on March 2, 2026. The consensus among analysts remains positive, with a general buy recommendation and a mean target price reflecting optimism in GMAB's prospects.
About GMAB
GMAB is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of cancer and other serious diseases. The company leverages its proprietary technology platforms to create novel treatments aimed at improving patient outcomes. Headquartered in Denmark, GMAB works on advancing its pipeline of products through various stages of clinical development.
Bottom Line
HC Wainwright's reiterated buy rating and $38 target for GMAB underscore continued confidence in the company's potential. Investors keep a close eye on GMAB due to its promising pipeline and the stock's dynamic trading activity. As always, it's important to remember that these analyst ratings are based on past data and projections, which may not necessarily predict future performance.
Get Genmab A/S alerts
New 13F filings, insider trades, and analyst moves on $GMAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.